+52.7%
DRAM vs MRNA
+364.0%
-311.2%
-54.2%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 5y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -2.9% | -3.4% | +0.6% | -2.8% |
| 7D | +7.9% | -12.1% | +20.0% | +8.3% |
| 30D | -15.4% | -1.3% | -14.1% | -15.3% |
| 3M | -25.5% | +250.9% | -276.5% | -27.3% |
| 6M | -22.3% | +343.0% | -365.3% | -33.6% |
| All | +52.7% | +364.0% | -311.2% | +26.1% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 5y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
5y analysis · Full analysis span regression · 6 months rolling